Corporate Overview

Schrödinger Offices Worldwide- Roll over
a location to view contact information

Schrödinger is a scientific leader in developing state-of-the-art chemical simulation software for use in pharmaceutical and biotechnology research.

The company's products range from general molecular modeling programs to a full-featured suite of drug design software including both ligand and structure based methods. Founded in 1990, Schrödinger has operations in New York, Oregon, and California, as well as in Germany and England. Schrödinger's customers include a large majority of the top 50 global pharmaceutical companies, hundreds more pharmaceutical and biotech companies, and countless universities, non-profit institutions, and governmental agencies, including supercomputing centers.

Schrödinger's research and development activities have been guided by the belief that advanced computational techniques will be an increasingly critical component of the way chemists design molecules. Working closely with a distinguished group of leading academic and industrial scientists, Schrödinger has achieved breakthroughs in the fields of quantum chemistry, molecular modeling, drug design, and protein structure determination. Today, the predictive power of Schrödinger's software allows scientists to accelerate their research and development activities, reduce research costs, and make novel discoveries that might not be possible with other computational or experimental approaches.

> January 8th, 2010

Schrödinger Acquires PyMOLGO

> December 3rd, 2009

Schrödinger Signs Collaboration Agreement with Novira TherapeuticsGO

> November 2nd, 2009

Schrödinger Announces Update 2 to Suite 2009GO

> March 12th, 2010

Schrödinger at Cutting Edge Approaches to Drug Design 2010 (CEA2DD), School of Oriental and African Studies, Russell Square, London, UK, March 12, 2010GO

> March 21st-25th, 2010

Schrödinger at Spring 2010 ACS National Meeting & Exposition, San Francisco, CA, March 21-25, 2010GO

> March 26th, 2010

Schrödinger Workshop "From Structural Biology to Drug Discovery," Universität Hamburg, Hamburg, Germany, March 26, 2010GO